Cynthia Butitta Insider Sell
Cynthia Butitta is the COO and CFO of Kite Pharma Inc. She a few days ago made a sale of 10,000 shares in the professional & scientific & and technical services’s company with the deal value amounting to $558,672 U.S. Dollars. The number is according to the documented price of $55.9 for each one share. Cynthia Butitta now indirectly has ownership of 0 shares. She also directly has ownership of 75507 shares. In total she holds a stake of 0.16%.
Kite Pharma Inc Sentiment and Fundamentals
It is difficult to make conclusions about Kite Pharma Inc’s future just from Cynthia Butitta’s sale because in this filing, the insider also revealed option transactions. In the form, it was reported that Cynthia exercised options for 10,000 shares with average price 1.4, worth 13,500. nine specialist analysts that cover Kite Pharma Inc fundamentals predict earnings per share of $-2.05 for the year 2015.
Chart analysis reveals Kite Pharma Inc’s share price lost 17.29% in the last 175 days. And this downward trend looks set to continue. OctaFinance’s trend-following model, coupled with Cynthia Butitta’s new stock investment, certainly helps us to grade this stock a SELL.
Institutional Ownership
Review of 13F SEC filings disclose that 151 institutional players own shares of Kite Pharma Inc. In the last quarter, the company in focus had 68.17% institutional ownership. That is a high interest. Its up 19.31% from Q1 2015. These hedge funds increased the total shares they own by 4.83 million to 29.82 million this quarter. A total of 28 funds closed their positions in Kite Pharma Inc and 28 reduced their holdings. There were 40 funds that created new positions and 66 funds that added to their positions.
This stock is held by five institutional holders in their Top 10 stock holdings. Some of them are: Wildcat Capital Management Llc, Rtw Investments Llc, Ecor1 Capital Llc, Lamond Capital Partners Llc, Dsam Partners Llp.
Wildcat Capital Management Llc is the most bullish institutional investor on Kite Pharma Inc, with ownership of 2.36 million shares as of Q2 2015 for 49.28% of the fund’s portfolio. Rtw Investments Llc is another bullish investment manager owning 400,000 shares of the company or 7.10% of their stocks portfolio. The stock is also 15.15% of the fund’s AUM. Further The California-based fund Ecor1 Capital Llc have 5.72% of their stock portfolio invested in the stock for 281,400 shares. Lamond Capital Partners Llc disclosed it had purchased a stake worth 6.53% of the fund’s stock portfolio in Kite Pharma Inc. Guy Shahar’s Dsam Partners Llp is also very optimistic about the firm, owning 342,188 shares or 3.79% of their stock portfolio.
Kite Pharma NASDAQ:KITE Company Profile
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Company’s lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.
Company Website: Kite Pharma
The company has 72 employees. At the moment its market cap is: $2.44 billion and it has 46.92 million outstanding shares. Currently it has 70.00% shareholders and the institutional ownership is 70.00%. Kite Pharma Inc was formed in Delaware on 2009-06-01. The stock closed at $55.68 yesterday and it had average 2 days volume of 289632 shares. It is up from the 30 days average shares volume of 250155. Kite Pharma Inc has a 52w low of $27.02 and a one year high of $89.20. The current price is below the 200 days simple moving average. Kite Pharma Inc last issued its quarterly earnings report on 08/10/2015. The company reported -0.48 EPS for the quarter, missing the consensus estimate of -0.41 by 0.07. The company had a revenue of 4.40 million for 6/30/2015 and 2.88 million for 3/31/2015. Therefore, the revenue was 1.52 million up.
* The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27 - 2015.
* 108 - 839 of the 435 - 394 shares originally subject to the stock option vested and became exercisable on December 15 - 2014 - and 9 - 071 shares vest monthly thereafter.
